Kinase inhibitors: the road ahead
Crossref DOI link: https://doi.org/10.1038/nrd.2018.21
Published Online: 2018-03-16
Published Print: 2018-05
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Ferguson, Fleur M.
Gray, Nathanael S.
Text and Data Mining valid from 2018-03-16
Article History
First Online: 16 March 2018
Competing interests
: N.S.G. is a scientific founder and equity holder in C4, Petra, Syros and Gatekeeper Pharmaceuticals.